BioSpace News Archive

CytomX Therapeutics, Inc. today announced that preclinical data supporting the ongoing development of its conditionally activated cytokine program will be presented at the American Association for Cancer Research (AACR) Annual Meeting on April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Ring Therapeutics today announced the appointments of Francois Nader, MD, MBA, David Epstein, MBA, and B. Lynne Parshall, Esq., to its Board of Directors.

CinCor Pharma, Inc. announced that the Company will be added to the Russell 2000® and Russell 3000® Indexes, effective on Friday, March 18, 2022, as part of the quarterly initial public offering additions.

Fulcrum Therapeutics, Inc. today announced that it will host a Key Opinion Leader (KOL) meeting on Thursday, March 24, 2022 from 10:00am – 12:00pm ET to discuss the company’s program with losmapimod for facioscapulohumeral muscular dystrophy (FSHD).

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the fourth quarter and year ended December 31, 2021 and provided a business update.

Harmony Biosciences Holdings, Inc. today announced applications open on “World Sleep Day”, Friday, March 18, 2022, for its Patients at the Heart Program.

BioLife Solutions, Inc. announced today an additional delay in the filing of its Annual Report on Form 10-K for the year ended December 31, 2021 (the “Form 10-K”).

Enveda Biosciences, a leading biotechnology company harnessing nature’s chemistry to develop next-generation small molecule therapies, announced the addition of three leaders to further scale and accelerate its translational drug development efforts.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), today announced that physicians at the Clinica Porto Azul in Barranquilla, Colombia successfully implanted the Company’s PortIO™ Intraosseous Infusion System in three patients—the first human implants of the device—as part of its IRB-approved first-in-human (FIH) clinical study of up to 40 patients.

Aldeyra Therapeutics, Inc. today reported recent corporate highlights and financial results for the year ended December 31, 2021.